Clinical radiobiology in 2008

Radiotherapy and Oncology

Volumn 86, Issue 3, 2008, Pages 295-299

  Begg, Adrian ^a   van der Kogel, Albert ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MICRORNA;

CANCER RADIOTHERAPY; CANCER RESEARCH; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EDITORIAL; GENE EXPRESSION; HYPOXIA; PRIORITY JOURNAL; RADIOBIOLOGY; RNA INTERFERENCE;

HUMANS; NEOPLASMS; RADIOBIOLOGY;

EID: 40249092815     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.02.004     Document Type: Editorial

References (71)

1. Aerts H.J., Dubois L., Hackeng T.M., Straathof R., Chiu R.K., Lieuwes N.G., et al. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiother Oncol 83 (2007) 326-332
2. Alsner J., Rødningen O.K., and Overgaard J. Differential gene expression before and after ionizing radiation of subcutaneous fibroblasts identifies breast cancer patients resistant to radiation-induced fibrosis. Radiother Oncol 83 (2007) 261-266
3. Baumann M., Krause M., Dikomey E., Dittmann K., Dörr W., Kasten-Pisula U., et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83 (2007) 238-248
4. Bristow R.G., Ozcelik H., Jalali F., Chan N., and Vesprini D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol 83 (2007) 220-230
5. Dewhirst M.W., Cao Y., Li C.Y., and Moeller B. Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol 83 (2007) 249-255
6. Dubois L., Douma K., Supuran C.T., Chiu R.K., van Zandvoort M.A., Pastorekova S., et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 83 (2007) 367-373
7. Eriksen J.G., Overgaard J., and Danish Head and Neck Cancer Study Group (DAHANCA). Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother Oncol 83 (2007) 383-388
8. Kasten-Pisula U., Windhorst S., Dahm-Daphi J., Mayr G., and Dikomey E. Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis. Radiother Oncol 83 (2007) 296-303
9. Koritzinsky M., Rouschop K.M., van den Beucken T., Magagnin M.G., Savelkouls K., Lambin P., et al. Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol 83 (2007) 353-361
10. Krause M., Prager J., Zhou X., Yaromina A., Dörfler A., Eicheler W., et al. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumourigenic cells?. Radiother Oncol 83 (2007) 316-325
11. Lavin M.F., and Kozlov S. DNA damage-induced signalling in ataxia-telangiectasia and related syndromes. Radiother Oncol 83 (2007) 231-237
12. Magagnin M.G., Sergeant K., van den Beucken T., Rouschop K.M., Jutten B., Seigneuric R., et al. Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiother Oncol 83 (2007) 340-345
13. Meyer A., Wilhelm B., Doerk T., Bremer M., Baumann R., Karstens J.H., et al. ATM missense variant P1054R predisposes to prostate cancer. Radiother Oncol 83 (2007) 283-288
14. Nordsmark M., Eriksen J.G., Gebski V., Alsner J., Horsman M.R., and Overgaard J. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83 (2007) 389-397
15. Rachidi W., Harfourche G., Lemaitre G., Amiot F., Vaigot P., and Martin M.T. Sensing radiosensitivity of human epidermal stem cells. Radiother Oncol 83 (2007) 267-276
16. Said H.M., Hagemann C., Staab A., Stojic J., Kühnel S., Vince G.H., et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 83 (2007) 398-405
17. Schütze C., Bergmann R., Yaromina A., Hessel F., Kotzerke J., Steinbach J., et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol 83 (2007) 311-315
18. Seigneuric R., Starmans M.H., Fung G., Krishnapuram B., Nuyten D.S., van Erk A., et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol 83 (2007) 374-382
19. van den Beucken T., Magagnin M.G., Savelkouls K., Lambin P., Koritzinsky M., and Wouters B.G. Regulation of Cited2 expression provides a functional link between translational and transcriptional responses during hypoxia. Radiother Oncol 83 (2007) 346-352
20. Weppler S.A., Li Y., Dubois L., Lieuwes N., Jutten B., Lambin P., et al. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol 83 (2007) 333-339
21. Wiegman E.M., Blaese M.A., Loeffler H., Coppes R.P., and Rodemann H.P. TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiother Oncol 83 (2007) 289-295
22. De Schutter H., Barbé B., Spaepen M., Begg A.C., Balm A., Gregoire V., et al. Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1. Radiother Oncol 80 (2006) 143-150
23. Durand R.E., and Aquino-Parsons C. The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemo-radiotherapy. Radiother Oncol 80 (2006) 138-142
24. Eke I., Sandfort V., Mischkus A., Baumann M., and Cordes N. Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. Radiother Oncol 80 (2006) 178-184
25. Handrick R., Rübel A., Faltin H., Eibl H., Belka C., and Jendrossek V. Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother Oncol 80 (2006) 199-206
26. Jaal J., and Dörr W. Radiation-induced damage to mouse urothelial barrier. Radiother Oncol 80 (2006) 250-256
27. Klokov D., MacPhail S.M., Banáth J.P., Byrne J.P., and Olive P.L. Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol 80 (2006) 223-229
28. Krause M., Zips D., Thames H.D., Kummermehr J., and Baumann M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol 80 (2006) 112-122 [Epub 2006 August 17, Review]
29. Lukacova S., Overgaard J., Alsner J., and Horsman M.R. Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models. Radiother Oncol 80 (2006) 165-171
30. Mason K.A., Neal R., Hunter N., Ariga H., Ang K., and Milas L. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother Oncol 80 (2006) 192-198
31. Raju U., Ariga H., Koto M., Lu X., Pickett J., Valdecanas D., et al. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiother Oncol 80 (2006) 185-191
32. Troost E.G., Laverman P., Kaanders J.H., Philippens M., Lok J., Oyen W.J., et al. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol 80 (2006) 157-164
33. Wissink E.H., Verbrugge I., Vink S.R., Schader M.B., Schaefer U., Walczak H., et al. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother Oncol 80 (2006) 214-222
34. Bussink J., Kaanders J.H., and van der Kogel A.J. Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiother Oncol 82 (2007) 10-17
35. Ohneseit P.A., Krebiehl G., Dittmann K., Kehlbach R., and Rodemann H.P. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro. Radiother Oncol 82 (2007) 229-238
36. Weppler S.A., Krause M., Zyromska A., Lambin P., Baumann M., and Wouters B.G. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 82 (2007) 96-104
37. West C.M., Elliott R.M., and Burnet N.G. The genomics revolution and radiotherapy. Clin Oncol (R Coll Radiol) 19 (2007) 470-480
38. van Haaften G., Romeijn R., Pothof J., Koole W., Mullenders L.H., Pastink A., et al. Identification of conserved pathways of DNA-damage response and radiation protection by genome-wide RNAi. Curr Biol 16 (2006) 1344-1350
39. Kasten-Pisula U., Vronskaja S., Overgaard J., and Dikomey E. In normal human fibroblasts variation in DSB repair capacity cannot be ascribed to radiation-induced changes in the localisation, expression or activity of major NHEJ proteins. Radiother Oncol 86 (2008) 321-328
40. Vermeulen C., Verwijs-Janssen M., Begg A.C., and Vens C. Cell cycle phase dependent role of DNA repair and survival after ionizing radiation. Radiother Oncol 86 (2008) 391-398
41. Huxham L.A., Kyle A.H., Baker J.H., McNicol K.L., and Minchinton A.I. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother Oncol 78 (2006) 138-145
42. Jonathan R.A., Wijffels K.I., Peeters W., de Wilde P.C., Marres H.A., Merkx M.A., et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 79 (2006) 288-297
43. Jordan B.F., Beghein N., Crokart N., Baudelet C., Grégoire V., and Gallez B. Preclinical safety and antitumor efficacy of insulin combined with irradiation. Radiother Oncol 81 (2006) 112-117
44. Quennet V., Yaromina A., Zips D., Rosner A., Walenta S., Baumann M., et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 81 (2006) 130-135
45. Wergin M.C., Roos M., Inteeworn N., Laluhovà D., Allemann K., and Kaser-Hotz B. The influence of fractionated radiation therapy on plasma vascular endothelial growth factor (VEGF) concentration in dogs with spontaneous tumors and its impact on outcome. Radiother Oncol 79 (2006) 239-244
46. Yaromina A., Zips D., Thames H.D., Eicheler W., Krause M., Rosner A., et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol 81 (2006) 122-129
47. Fujii H., Sakata K.I., Katsumata Y., Sato R., Kinouchi M., Someya M., et al. Tissue oxygenation in a murine SCC VII tumor after X-ray irradiation as determined by EPR spectroscopy. Radiother Oncol 86 (2008) 354-360
48. Tomita N., Shibamoto Y., Ito M., Ogino H., Sugie C., Ayakawa S., et al. Biological effect of intermittent radiation exposure in vivo: recovery from sublethal damage versus reoxygenation. Radiother Oncol 86 (2008) 369-374
49. Bayer C., Schilling D., Hoetzel J., Egermann H.P., Zips D., Yaromina A., et al. PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. Radiother Oncol 86 (2008) 361-368
50. Sonveaux P. Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. Radiother Oncol 86 (2008) 300-313
51. Akudugu J.M., Bell R.S., Catton C., Davis A.M., Griffin A.M., O'Sullivan B., et al. Wound healing morbidity in STS patients treated with preoperative radiotherapy in relation to in vitro skin fibroblast radiosensitivity, proliferative capacity and TGF-beta activity. Radiother Oncol 78 (2006) 17-26
52. Brunner T.B., Ernst-Stecken A., Jeske I., Grabenbauer G.G., Sauer R., and Distel L. Molecular verification of stereotactic radiotherapy in rats using ATMpS1981 immunofluorescence. Radiother Oncol 79 (2006) 109-114
53. Hill R.P., Kaspler P., Griffin A.M., O'Sullivan B., Catton C., Alasti H., et al. Studies of the in vivo radiosensitivity of human skin fibroblasts. Radiother Oncol 84 (2007) 75-83
54. Langan A.R., Khan M.A., Yeung I.W., Van Dyk J., and Hill R.P. Partial volume rat lung irradiation: the protective/mitigating effects of Eukarion-189, a superoxide dismutase-catalase mimetic. Radiother Oncol 79 (2006) 231-238
55. Machtay M., Scherpereel A., Santiago J., Lee J., McDonough J., Kinniry P., et al. Systemic polyethylene glycol-modified (PEGylated) superoxide dismutase and catalase mixture attenuates radiation pulmonary fibrosis in the C57/bl6 mouse. Radiother Oncol 81 (2006) 196-205
56. Millar W.T., and Hopewell J.W. Effects of very low dose-rate (90)Sr/(90)Y exposure on the acute moist desquamation response of pig skin. Radiother Oncol 83 (2007) 187-195
57. Arenas M., Gil F., Gironella M., Hernández V., Biete A., Piqué J.M., et al. Time course of anti-inflammatory effect of low-dose radiotherapy: correlation with TGF-beta(1) expression. Radiother Oncol 86 (2008) 399-406
58. Hehlgans S., Eke I., Deuse Y., and Cordes N. Integrin-linked kinase: dispensable for radiation survival of three-dimensionally cultured fibroblasts. Radiother Oncol 86 (2008) 329-335
59. Borgmann K., Haeberle D., Doerk T., Busjahn A., Stephan G., and Dikomey E. Genetic determination of chromosomal radiosensitivities in G0- and G2-phase human lymphocytes. Radiother Oncol 83 (2007) 196-202
60. Distel L.V., Neubauer S., Keller U., Sprung C.N., Sauer R., and Grabenbauer G.G. Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. Radiother Oncol 81 (2006) 257-263
61. Söderlund K., Skoog L., Fornander T., and Askmalm M.S. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol 84 (2007) 242-251
62. Rødningen O.K., Børresen-Dale A.L., Alsner J., Hastie T., and Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol 86 (2008) 314-320
63. Olive P.L., Banath J.P., and Keyes M. Residual gammaH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy. Radiother Oncol 86 (2008) 336-346
64. Burlage F.R., Roesink J.M., Faber H., Vissink A., Langendijk J.A., Kampinga H.H., et al. Optimum dose range for the amelioration of long term radiation-induced hyposalivation using prophylactic pilocarpine treatment. Radiother Oncol 86 (2008) 347-353
65. Wanner G., Mayer C., Kehlbach R., Rodemann H.P., and Dittmann K. Activation of protein kinase Cepsilon stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. Radiother Oncol 86 (2008) 383-390
66. Dittmann K., Mayer C., and Kehlbach R. The radioprotector Bowman-Birk proteinase inhibitor stimulates DNA-repair via epidermal growth factor receptor phosphorylation and nuclear transport. Radiother Oncol 86 (2008) 375-382
67. Bieler A., Mantwill K., Holzmüller R., Jürchott K., Kaszubiak A., Stärk S., et al. Impact of radiation therapy on the oncolytic adenovirus dl520: Implications on the treatment of glioblastoma. Radiother Oncol 86 (2008) 419-427
68. Dittmann K., Mayer C., Wanner G., Kehlbach R., and Rodemann H.P. The radioprotector O-phospho-tyrosine stimulates DNA-repair via epidermal growth factor receptor- and DNA-dependent kinase phosphorylation. Radiother Oncol 84 (2007) 328-334
69. Supiot S., Zhao H., Wiman K., Hill R.P., and Bristow R.G. PRIMA-1 radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol 86 (2008) 407-411
70. Haykal J., Fernainy P., Itani W., Haddadin M., Geara F., Smith C., et al. Radiosensitization of EMT6 mammary carcinoma cells by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide. Radiother Oncol 86 (2008) 412-418
71. Folkvord S., Flatmark K., Seierstad T., Røe K., Rasmussen H., and Ree A.H. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?. Radiother Oncol 86 (2008) 428-434